Document Detail


Determinants of patient screen failures in Phase 1 clinical trials.
MedLine Citation:
PMID:  23135779     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective Certain eligibility criteria for Phase 1 cancer clinical trials may impede successful patient enrollment onto a study. We evaluated patient-specific or study-specific reasons for screen failures on Phase 1 oncology clinical trials and discuss factors which may inhibit subject enrollment. Methods Thirty-eight Phase 1 clinical trials for solid tumors meeting eligibility criteria and opened for enrollment between February 2006 and February 2011 at one oncology Phase 1 program were examined. Categorical reasons for screen failures and patients' demographics were examined and compared to characteristics of patients that successfully enrolled on a Phase 1 trial. Results There were a total of 583 successful Phase 1 enrollment and dose administration events out of 773 Phase 1 consent events (75.4 % dose success rate). The three most common reasons for screen failure were: out of protocol-specified range for chemistry, development of an interval medical issue that precluded proceeding with study participation, and subject declining participation after signing consent. Living further away from the Phase 1 program and receipt of fewer prior lines of systemic chemotherapy were significantly associated with increased screen failures. Conclusion Screen failures for Phase 1 studies are not uncommon (24.6 %). When a protocol required tumor or host analyte is not required, most screen failures are due to out of protocol-specified range for chemistry or the development of an interval medical issue. Screen failure rates were increased when patients had longer travel distances and fewer prior lines of systemic chemotherapy.
Authors:
Alexandra McKane; Chao Sima; Ramesh K Ramanathan; Gayle Jameson; Cathy Mast; Erica White; Sharon Fleck; Molly Downhour; Daniel D Von Hoff; Glen J Weiss
Related Documents :
23327049 - Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell ...
24055429 - The predictive value of positive urine cytology for outcomes following radical nephrour...
23975509 - A phase ii study of cisplatin /s-1 in patients with carcinomas of unknown primary site.
24604949 - Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma...
24192519 - Endocervical-like versus intestinal-type mucinous borderline ovarian tumors: a large re...
24300729 - Clinical significance of cancer in radical prostatectomy specimens: analysis from a con...
21606209 - Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for...
22198429 - Hypofractionated image-guided radiation therapy for patients with limited volume metast...
17041749 - Indication and benefit of pelvic sidewall dissection for rectal cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, 10510 N 92nd St. Ste 200, Scottsdale, AZ, 85258, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib...
Next Document:  Evaluation of the retinal changes in patients with chronic migraine.